title: Poly(ADP-ribose)polymerase inhibition counteracts renal hypertrophy and multiple manifestations of peripheral neuropathy in diabetic Akita mice.
abstract: Poly(ADP-ribose) polymerase (PARP) activation has been implicated in the pathogenesis of diabetic complications, including nephropathy and peripheral neuropathy. This study aimed at evaluating the manifestations of both complications in diabetic Akita mice, a model of Type 1 (insulin-dependent) diabetes, and their amenability to treatment with the potent PARP inhibitor, 10-(4-methyl-piperazin-1-ylmethyl)-2H-7-oxa-1,2-diaza-benzo[de] anthracen-3-one (GPI-15427). Male non-diabetic C57Bl6/J and diabetic C57Bl/6-Ins2Akita/J (Akita) mice were maintained with or without treatment with GPI-15427, 30 mg/kg/day, for 4 weeks starting from 16 weeks of age. Sixteen week-old Akita mice displayed sensory nerve conduction velocity (SNCV) deficit, whereas the motor nerve conduction velocity (MNCV) tended to decrease, but the difference with controls did not achieve statistical significance. They also developed thermal and mechanical hypoalgesia and tactile allodynia. SNCV deficit, mechanical hypoalgesia, and tactile allodynia progressed with age whereas the severity of thermal hypoalgesia was similar in 16- and 20-week-old Akita mice. PARP inhibition alleviated, although it did not completely reverse, SNCV deficit, thermal and mechanical hypoalgesia and tactile allodynia. Sixteen-week-old Akita mice displayed MNCV deficit (41.3±2.5 vs. 51.0±1.2 m/sec in non-diabetic controls, P<0.01), axonal atrophy of myelinated fibers, kidney hypertrophy, and albuminuria. MNCV slowing, axonal atrophy, and kidney hypertrophy, but not albuminuria, were less severe in GPI-15427-treated age-matched Akita mice. Neuroprotective and nephroprotective effects of PARP inhibition were not due to alleviation of diabetic hyperglycemia, or peripheral nerve p38 mitogen-activated protein kinase activation. GPI-15427 did not affect any variables in control mice. In conclusion, the findings support an important role for PARP activation in diabetic peripheral neuropathy and kidney hypertrophy associated with Type 1 diabetes, and provide rationale for development and further studies of PARP inhibitors, for the prevention and treatment of these complications.
authors: Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA 70808, USA.
authors: Viktor R
authors: VR
authors: Drel
authors: Pal
authors: P
authors: Pacher
authors: Roman
authors: R
authors: Stavniichuk
authors: Weizheng
authors: W
authors: Xu
authors: Jie
authors: J
authors: Zhang
authors: Tamara M
authors: TM
authors: Kuchmerovska
authors: Barbara
authors: B
authors: Slusher
authors: Irina G
authors: IG
authors: Obrosova
references: Curr Opin Drug Discov Devel. 2010 Sep;13(5):577-86
references: 20812149
references: Free Radic Biol Med. 2010 Sep 15;49(6):1036-45
references: 20599608
references: Diabetes Care. 2006 Jul;29(7):1538-44
references: 16801576
references: Biochem Pharmacol. 2010 Apr 1;79(7):1007-14
references: 19945439
references: Neurobiol Dis. 2006 Jun;22(3):669-76
references: 16624563
references: Diabetes. 2006 Jul;55(7):1946-53
references: 16804062
references: Invest Ophthalmol Vis Sci. 2009 Apr;50(4):1778-90
references: 19098320
references: Diabetes. 2004 Mar;53(3):711-20
references: 14988256
references: Diabetes Metab Res Rev. 2008 May-Jun;24 Suppl 1:S3-6
references: 18442166
references: Diabetologia. 2006 May;49(5):1081-8
references: 16528572
references: Diabetes. 2006 Dec;55(12):3335-43
references: 17130477
references: Diabetes. 2004 Nov;53(11):2960-7
references: 15504977
references: Nitric Oxide. 2006 Dec;15(4):344-50
references: 16644248
references: Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3270-5
references: 11854472
references: Diabetes Obes Metab. 2008 Jan;10(1):64-74
references: 17970755
references: Diabetes. 2008 Jun;57(6):1693-701
references: 18362211
references: J Pharmacol Exp Ther. 2004 Jul;310(1):247-55
references: 14999056
references: J Androl. 2010 Nov-Dec;31(6):547-51
references: 20671140
references: Free Radic Biol Med. 2008 Mar 15;44(6):972-81
references: 17976390
references: Diabetes. 2007 Oct;56(10):2598-608
references: 17626889
references: Brain Res. 2006 Oct 20;1116(1):206-14
references: 16938273
references: Blood. 2010 Nov 25;116(22):4578-87
references: 20739657
references: Diabetes. 2009 Apr;58(4):934-45
references: 19136650
references: N Engl J Med. 2009 Jul 9;361(2):123-34
references: 19553641
references: Diabetes. 2006 Nov;55(11):3004-12
references: 17065336
references: Nat Med. 2001 Jan;7(1):108-13
references: 11135624
references: FASEB J. 2001 Nov;15(13):2508-14
references: 11689477
references: Biochim Biophys Acta. 2010 Nov;1802(11):1020-7
references: 20621183
references: Free Radic Biol Med. 2011 May 15;50(10):1400-9
references: 21300148
references: Diabetes. 2004 Jul;53(7):1851-6
references: 15220210
references: Diabetes. 1997 May;46(5):887-94
references: 9133560
references: Circ Res. 2009 Jul 31;105(3):287-94
references: 19423844
references: Exp Neurol. 2009 Mar;216(1):207-18
references: 19111542
references: Diabetes Care. 2006 Nov;29(11):2365-70
references: 17065669
references: Endocrinology. 2009 Dec;150(12):5273-83
references: 19854869
references: Nat Rev Drug Discov. 2005 May;4(5):421-40
references: 15864271
references: Brain. 2001 Dec;124(Pt 12):2448-58
references: 11701599
references: Endocrinology. 2010 Jun;151(6):2547-55
references: 20357221
references: Diabetes. 2006 Jun;55(6):1686-94
references: 16731831
references: Diabetes. 2008 Jun;57(6):1664-73
references: 18332094
references: J Am Soc Nephrol. 2005 Jan;16(1):27-45
references: 15563560
references: Diabetes Care. 2010 Oct;33(10):2285-93
references: 20876709
references: Diabetes. 2002 Feb;51(2):514-21
references: 11812763
references: Drugs. 2010 Dec 3;70(17):2229-45
references: 21080740